We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Studies assessing bronchoscopic lung volume reduction ...
Quantitative CT in AATD linked airway wall thickening and bronchiectasis to lung function, while wall thickness best ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Augmentation therapy increased survival in patients with ...
About Alpha-1 Antitrypsin Deficiency-Associated Liver Disease AATD is a rare genetic disorder associated with liver disease in children and adults and pulmonary disease in adults. AATD is estimated to ...
Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its ...
Alpha-1 antitrypsin deficiency, AATD, is an inherited disease affecting the lung, liver, and, rarely, skin. Alpha-1 antitrypsin, AAT, is a protease inhibitor of the proteolytic enzyme elastase.
- Dicerna to Lead Global Clinical Development and U.S. Commercialization of its DCR-A1AT and Alnylam’s ALN-AAT02 Investigational Therapeutics for the Treatment of Alpha-1 Liver Disease; Alnylam ...
GAINESVILLE, Fla. and CAMBRIDGE, Mass. and WORCESTER, Mass., June 08, 2017 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC) and the University of Massachusetts Medical School ...
MOLINE, Ill. — November is Alpha-1 Awareness Month, a time dedicated to increasing understanding of Alpha-1 Antitrypsin Deficiency, a rare genetic condition that can cause serious lung and liver ...
Alpha-1 antitrypsin deficiency (AATD) is a hereditary condition characterised by the misfolding of the alpha-1 antitrypsin (AAT) protein, resulting in its hepatic accumulation and compromised protease ...
Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback